130636-43-0 Usage
General Description
Nifekalant is a class III antiarrhythmic agent, primarily used in the treatment of arrhythmias, specifically ventricular tachycardia and ventricular fibrillation. It was developed as an alternative to amiodarone, exhibiting relatively selective potassium ion channel blocking action, and consequently shows minimal adverse effects on hemodynamics. Nifekalant is predominantly used in Japan and is recognized for its rapid onset of action and excellent efficacy, enhancing its utility in emergency settings. However, due to the risk of proarrhythmia, careful monitoring is essential when using this drug.
Check Digit Verification of cas no
The CAS Registry Mumber 130636-43-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,3 and 6 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 130636-43:
(8*1)+(7*3)+(6*0)+(5*6)+(4*3)+(3*6)+(2*4)+(1*3)=100
100 % 10 = 0
So 130636-43-0 is a valid CAS Registry Number.
InChI:InChI=1/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H
130636-43-0Relevant articles and documents
A method for preparing high-purity hydrochloric acid Nepal non-Kalland
-
Paragraph 0082; 0083, (2017/01/31)
The invention discloses a preparation method of nifekalant hydrochloride. The preparation method comprises the following steps of: performing aminolysis on 6-imino-1,3-dimethyluracil to obtain 1,3-dimethyl-6-(2-ethoxy)aminouracil; esterfying 1,3-dimethyl-
Synthesis and pharmacological studies of N-substituted 6-[(2- aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents
Katakami,Yokoyama,Miyamoto,Mori,Kawauchi,Nobori,San-nohe,Kaiho,Kamiya
, p. 3325 - 3330 (2007/10/02)
A series of 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)- pyrimidinedione derivatives were synthesized and studied for their class III electrophysiological activity and class II (β-blocking) effects in in vitro and in vivo models. Structure-activity re
